But initially at least Canada was seen as an additional complication to completion of the TPP, a «difficult» negotiating
partner that brought its own baggage (such as a less
than robust IPR regime, a traditional antipathy to the interests of the brand - name pharmaceutical
manufacturers, a penchant for protecting so - called «cultural industries», and
other trade issues that did not align with US interests) that might have resonated with some of the
other TPP countries.